Cephalon

Aclaris raises $21M in Series A Financing

Thursday, October 25, 2012 07:30 AM

Aclaris Therapeutics, a privately held specialty pharmaceutical company focused on dermatological therapeutics, has secured $21 million in Series A financing.

More... »

Galleon names Brookes senior VP

Thursday, December 1, 2011 11:38 AM

Galleon Pharmaceuticals has named Lynne M. Brookes senior vice president and chief business officer.

More... »

The CenterWatch Monthly, September 2011

Thursday, September 1, 2011 02:35 PM

Integrated CRO alliances growing but poorly executed

More... »

Cephalon shows positive results for Nuvigil

Friday, May 6, 2011 12:30 PM

Cephalon has positive results from a phase IV trial of nearly 400 people with excessive sleepiness associated with shift work disorder.  In the trial, Nuvigil (armodafinil) tablets improved shift-workers' overall clinical condition late in their shifts (i.e., 4:00 a.m. to 8:00 a.m.), including the commute home, compared to placebo.

More... »

Teva aquires Cephalon

Monday, May 2, 2011 01:01 PM

Teva Pharmaceutical and Cephalon have unanimously approved a definitive agreement under which Teva will acquire all of the outstanding shares of Cephalon for $81.50 per share in cash, or a total enterprise value of approximately $6.8 billion. The transaction is not conditioned on financing and is expected to be completed in the third quarter of 2011.

More... »

Valeant sets deadline for Cephalon

Thursday, April 21, 2011 12:59 PM

Canada-based Valeant Pharmaceuticals declared a May 12 deadline for its $5.7 billion bid for Cephalon and said it would walk if more than 50% of Cephalon shareholders do not consent to the offer, according to a Reuters report.

More... »

Cephalon rejects buyout, Valeant remains committed

Wednesday, April 6, 2011 11:52 AM

U.S.-based Cephalon has rejected Canadian-based Valeant Pharmaceuticals International's takeover bid, saying that the $5.7 billion offer, or $73.00 per share, is not in the best interests of shareholders, according to Pharma Times.

More... »

Pension fund sues Cephalon over Valeant buyout

Friday, April 1, 2011 01:54 PM

A Pennsylvania pension fund has filed a lawsuit and accused Cephalon officials of “failing to act” in the best interests of investors regarding a $5.7 billion buyout bid by rival Mississauga, Ontario-based Valeant Pharmaceuticals International, according to a Bloomberg report.

More... »

Valeant approaches Cephalon with buyout offer

Wednesday, March 30, 2011 01:55 PM

Valeant Pharmaceuticals International, based in Canada, has made an unsolicited bid to buy U.S.-based Cephalon, a biopharmaceutical company, for $5.7 billion.

More... »

Cephalon announces takeover bid for ChemGenex

Wednesday, March 30, 2011 01:51 PM

Cephalon and ChemGenex Pharmaceuticals announced that Cephalon's wholly-owned subsidiary, Cephalon CXS Holdings, intends to make a takeover bid for ChemGenex. ChemGenex is a hematology-focused Australian biopharmaceutical company developing its lead product candidate, Omapro, for the treatment of chronic myeloid leukemia (CML) patients. Omapro recently completed phase III clinical trials and ChemGenex plans to file a new drug application with the FDA in the second half of 2011.

More... »